Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 2/20 | 0.49 |
| ▸ | CPT1A | P50416 | 2/20 | 0.49 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 3/20 | 0.43 |
| ▸ | GPR142 | Q7Z601 | 8/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070119 | 0.90 | LIPE (0.47) | LIPETRPA1TRPV1 | |
| SCHEMBL10069712 | 0.89 | CPT1A (0.48) | CPT1AP2RY12KIT | |
| SCHEMBL10069537 | 0.87 | HSD11B1 (0.43) | CPT1AGPR142TRPA1P2RY12KIT | |
| SCHEMBL10070095 | 0.85 | CPT2 (0.49) | CPT2CPT1ACPT1BGPR142TRPA1 | |
| SCHEMBL10070093 | 0.85 | CPT1A (0.40) | CPT1ALIPEP2RY12KIT | |
| SCHEMBL1653319 | 0.84 | KIT (0.46) | P2RY12KIT | |
| SCHEMBL10069716 | 0.82 | HTR2B (0.42) | TRPA1P2RY12 | |
| SCHEMBL10070551 | 0.79 | AOC3 (0.45) | CPT2CPT1AKIT | |
| SCHEMBL10069541 | 0.79 | AKT1 (0.39) | CPT2CPT1ALIPEKIT | |
| SCHEMBL10070517 | 0.76 | TRPV1 (0.42) | CPT2CPT1ACPT1BLIPEGPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | CPT2 2583/4885CPT1A 1233/4885CPT1B 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.